Phencyclidine animal models of schizophrenia: Approaches from abnormality of glutamatergic neurotransmission and neurodevelopment

Neurochemistry International

Volumn 51, Issue 2-4 SPEC. ISS., 2007, Pages 173-184

  Mouri, Akihiro ^a,b   Noda, Yukihiro ^a,c   Enomoto, Takeshi ^a,d   Nabeshima, Toshitaka ^a,b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MEIJO UNIVERSITY   (Japan)

^c Faculty of Pharmacy   (Japan)

^d DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Animal model; Glutamate; Neurodevelopment; NMDA receptor; Phencyclidine; Schizophrenia

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; CYCLOSERINE; DESIPRAMINE; DEXTRO SERINE; EGLUMETAD; GLUTAMIC ACID; GLYCINE RECEPTOR ANTAGONIST; HALOPERIDOL; IMIPRAMINE; LEVOMEPROMAZINE; LY 487379; MANGANESEDICHLORO(3,10,13,20,26 PENTAAZATETRACYCLO[20.3.1.0(4,9).0(14,19)] 1(26),22(23),24 HEXACOSATRIENE); METABOTROPIC RECEPTOR AGONIST; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; PIMOZIDE; SEROTONIN 2A ANTAGONIST; SSR 504734; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; ZIPRASIDONE;

ATTENTION DEFICIT DISORDER; BEHAVIOR CHANGE; CHANNEL GATING; COGNITIVE DEFECT; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; ENVIRONMENTAL FACTOR; FORCED SWIMMING TEST; HUMAN; HYPERACTIVITY; IMMOBILIZATION; LEARNING; LEARNING TEST; MEMORY; NEGATIVE SYNDROME; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROBABILITY; REVIEW; RODENT; SCHIZOPHRENIA; SECOND TRIMESTER PREGNANCY; SENSORIMOTOR FUNCTION; SOCIAL INTERACTION; SOCIOPATHY; SYMPTOM; VIRAL CONTAMINATION; WORKING MEMORY;

ANIMALS; ANIMALS, NEWBORN; BRAIN; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; PHENCYCLIDINE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

ANIMALIA; RATTUS; RODENTIA;

EID: 34547459107     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2007.06.019     Document Type: Review

References (101)

1. Abdul-Monim Z., Neill J.C., and Reynolds G.P. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J. Psychopharmacol. 21 (2006) 198-205
2. Abdul-Monim Z., Reynolds G.P., and Neill J.C. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J. Psychopharmacol. 17 (2003) 57-66
3. Abdul-Monim Z., Reynolds G.P., and Neill J.C. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav. Brain Res. 169 (2006) 263-273
4. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney Jr. W.E., and Jones E.G. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci. 16 (1996) 19-30
5. Allen R.M., and Young S.J. Phencyclidine-induced psychosis. Am. J. Psychiatry 135 (1978) 1081-1084
6. Andersen J.D., and Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine. Neuropsychopharmacology 29 (2004) 1080-1090
7. Artaloytia J.F., Arango C., Lahti A., Sanz J., Pascual A., Cubero P., Prieto D., and Palomo T. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am. J. Psychiatry 163 (2006) 488-493
8. Bakshi V.P., and Geyer M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122 (1995) 198-201
9. Bakshi V.P., Swerdlow N.R., and Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271 (1994) 787-794
10. Beasley C.L., and Reynolds G.P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizo Res. 24 (1997) 349-355
11. Birrell J.M., and Brown V.J. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci. 20 (2000) 4320-4324
12. Braff D., Stone C., Callaway E., Geyer M., Glick I., and Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15 (1978) 339-343
13. Brooks W.J., Weeks A.C., Leboutillier J.C., and Petit T.L. Altered NMDA sensitivity and learning following chronic developmental NMDA antagonism. Physiol. Behav. 62 (1997) 955-962
14. Carlsson A., Hansson L.O., Waters N., and Carlsson M.L. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci. 61 (1997) 75-94
15. Clancy B., Darlington R.B., and Finlay B.L. Translating developmental time across mammalian species. Neuroscience 105 (2001) 7-17
16. Cochran S.M., Kennedy M., McKerchar C.E., Steward L.J., Pratt J.A., and Morris B.J. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmcology 28 (2003) 265-275
17. Corbett R., Zhou L., Sorensen S.M., and Mondadori C. Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice. Neuropsychopharmacology 21 (1999) S211-S218
18. Cosgrove J., and Newell T.G. Recovery of neuropsychological functions during reduction in use of phencyclidine. J. Clin. Psychol. 47 (1991) 159-169
19. Depoortere R., Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., Poncelet M., Heaulme M., Santucci V., Decobert M., Cudennec A., Voltz C., Boulay D., Terranova J.P., Stemmelin J., Roger P., Marabout B., Sevrin M., Vige X., Biton B., Steinberg R., Francon D., Alonso R., Avenet P., Oury-Donat F., Perrault G., Griebel G., George P., Soubrie P., and Scatton B. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30 (2005) 1963-1985
20. Deschenes A., Goulet S., and Dore F.Y. Rule shift under long-term PCP challenge in rats. Behav. Brain Res. 167 (2006) 134-140
21. Dracheva S., Marras S.A., Elhakem S.L., Kramer F.R., Davis K.L., and Haroutunian V. N-methyl-d-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am. J. Psychiatry 158 (2001) 1400-1410
22. Egerton A., Reid L., McKerchar C.E., Morris B.J., and Pratt J.A. Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology 179 (2005) 77-84
23. Elliott R., McKenna P.J., Robbins T.W., and Sahakian B.J. Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. Psychol. Med. 25 (1995) 619-630
24. Ellison G., and Switzer R.C. Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport 5 (1993) 17-20
25. Emamian E.S., Karayiorgou M., and Gogos J.A. Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with Schizophrenia. J. Neurosci. 24 (2004) 1561-1564
26. Enomoto T., Noda Y., Mouri A., Shin E.J., Wang D., Murai R., Hotta K., Furukawa H., Nitta A., Kim H.C., and Nabeshima T. Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-d-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine. Mol. Pharmacol. 68 (2005) 1765-1774
27. Fletcher P.J., Tenn C.C., Rizos Z., Lovic V., and Kapur S. Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology 183 (2005) 190-200
28. Freed W.J., Bing L.A., and Wyatt R.J. Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice. Neuropharmacology 23 (1984) 175-181
29. Gemperle A.Y., Enz A., Pozza M.F., Luthi A., and Olpe H.R. Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study. Neuroscience 117 (2003) 681-695
30. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156 (2001) 117-154
31. Guan H.J., Dai J., and Zhu X.Z. Atypical antipsychotic effects of quetiapine fumarate in animal models. Acta Pharmacol. Sin. 21 (2000) 205-210
32. Guerrini L., Blasi F., and Denis-Donini S. Synaptic activation of NF-kappa B by glutamate in cerebellar granule neurons in vitro. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9077-9081
33. Hajszan T., Leranth C., and Roth R.H. Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. Biol. Psychiatry 60 (2006) 639-644
34. Harich S., Gross G., and Bespalov A. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl) 192 (2007) 511-519
35. Hashimoto K., Fujita Y., Shimizu E., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur. J. Pharmacol. 519 (2005) 114-117
36. Hashimoto T., Volk D.W., Eggan S.M., Mirnics K., Pierri J.N., Sun Z., Sampson A.R., and Lewis D.A. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 23 (2003) 6315-6326
37. Ichihara K., Nabeshima T., and Kameyama T. Dopaminergic agonists impair latent learning in mice: possible modulation by noradrenergic function. J. Pharmacol. Exp. Ther. 264 (1993) 122-128
38. Idris N.F., Repeto P., Neill J.C., and Large C.H. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and d-amphetamine in the rat. Psychopharmacology 179 (2005) 336-348
39. Itokawa M., Yamada K., Yoshitsugu K., Toyota T., Suga T., Ohba H., Watanabe A., Hattori E., Shimizu H., Kumakura T., Ebihara M., Meerabux J.M., Toru M., and Yoshikawa T. A microsatellite repeat in the promoter of the N-methyl-d-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics 13 (2003) 271-278
40. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
41. Jentsch J.D., Redmond D.E., Elsworth J.D., Taylor J.R., Youngren K.D., and Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277 (1997) 953-955
42. Jentsch J.D., Tran A., Le D., Youngren K.D., Phil M., and Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17 (1997) 92-99
43. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
44. Jentsch J.D., Taylor J.R., and Roth R.H. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19 (1998) 105-113
45. Keith V.A., Mansbach R.S., and Geyer M.A. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol. Psychiatry 30 (1991) 557-566
46. Kitaichi K., Yamada K., Hasegawa T., Furukawa H., and Nabeshima T. Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin. J. Pharmacol. Sci. (Jpn. J. Pharmacol.) 66 (1994) 181-189
47. Kitaichi K., Yamada K., Yoneda Y., Ogita K., Hasegawa T., Furukawa H., and Nabeshima T. Risperidone prevents the development of supersensitivity, but not tolerance to phencyclidine in rats treated with subacute phencyclidine. Life Sci. 56 (1995) 531-543
48. Komuro H., and Rakic P. Modulation of neuronal migration by NMDA receptors. Science 260 (1993) 95-97
49. Lewis D.A., and Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 25 (2002) 409-432
50. Li Z., Kim C.H., Ichikawa J., and Meltzer H.Y. Effect of repeated administration of phencyclidine on spatial performance in an eight-arm radial maze with delay in rats and mice. Pharmacol. Biochem. Behav. 75 (2003) 335-340
51. Lipska B.K., and Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23 (2000) 223-239
52. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., and Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch. Neurol. Psychiatry 81 (1959) 363-369
53. Mandillo S., Rinaldi A., Olverio A., and Mele A. Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetric drug-induced cognitive deficits. Behav. Pharmacol. 14 (2003) 533-544
54. Maren S. Neurobiology of Pavlovian fear conditioning. Annu. Rev. Neurosci. 24 (2001) 897-931
55. Martinez Z.A., Ellison G.D., Geyer M.A., and Swerdlow N.R. Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology 21 (1999) 28-39
56. Marquis J.P., Goulet S., and Dore F.Y. Schizophrenia-like syndrome inducing agent phencyclidine failed to impair memory for temporal order in rats. Neurobiol. Learn. Mem. 80 (2003) 158-167
57. Melone M., Vitellaro-Zuccarello L., Vallejo-Illarramendi A., Perez-Samartin A., Matute C., Cozzi A., Pellegrini-Giampietro D.E., Rothstein J.D., and Conti F. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol. Psychiatry 6 (2001) 380-386
58. Mouri A., Noda Y., Noda A., Nakamura T., Tokura T., Yura Y., Nitta A., Furukawa H., and Nabeshima T. Involvement of a dysfunctional dopamine-D1/N-methyl-d-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine. Mol. Pharmacol. 71 (2007) 1598-1609
59. Murai R., Noda Y., Matsui K., Kamei H., Mouri A., Matsuba K., Nitta A., Furukawa H., and Nabeshima T. Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling. Behav. Brain Res. 180 (2007) 152-160
60. Nabeshima T., Fukaya H., Yamaguchi K., Ishikawa K., Furukawa H., and Kameyama T. Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine. Eur. J. Pharmacol. 135 (1987) 23-33
61. Nabeshima T., Kozawa T., Furukawa H., and Kameyama T. Phencyclidine-induced retrograde amnesia in mice. Psychopharmacology (Berl) 89 (1986) 334-337
62. Nabeshima T., Yamada K., Yamaguchi K., Hiramatsu M., Furukawa H., and Kameyama T. Effect of lesions in the striatum, nucleus accumbens and medial raphe on phencyclidine-induced stereotyped behaviors and hyperactivity in rats. Eur. J. Pharmacol. 91 (1983) 455-462
63. Nagai T., Noda Y., Une T., Furukawa K., Furukawa H., Kan Q.M., and Nabeshima T. Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice. Neuroreport 14 (2003) 269-272
64. Noda A., Noda Y., Kamei H., Ichihara K., Mamiya T., Nagai T., Sugiura S., Furukawa H., and Nabeshima T. Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma1 receptors. Neuropsychopharmacology 24 (2001) 451-460
65. Noda Y., Kamei H., Mamiya T., Furukawa H., and Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 23 (2000) 375-387
66. Noda Y., Mamiya T., Furukawa H., and Nabeshima T. Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur. J. Pharmacol. 324 (1997) 135-140
67. Noda Y., and Nabeshima T. Neuropsychopharmacological study on an animal model for negative symptom of schizophrenia induced by repeated phencyclidine treatment. Yakugaku Zasshi 120 (2000) 677-682
68. Noda Y., Yamada K., Furukawa H., and Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br. J. Pharmacol. 116 (1995) 2531-2537
69. Nuechterlein K.H., and Dawson M.E. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr. Bull. 10 (1984) 160-203
70. Ohtsuki T., Sakurai K., Dou H., Toru M., Yamakawa-Kobayashi K., and Arinami T. Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia. Mol. Psychiatry 6 (2001) 211-216
71. Olney J.W., Labruyere J., and Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244 (1989) 1360-1362
72. Park S., and Holzman P.S. Schizophrenics show spatial working memory deficits. Arch. Gen. Psychiatry 49 (1992) 975-982
73. Pearlson G.D. Neurobiology of schizophrenia. Ann. Neurol. 48 (2000) 556-566
74. Qiao H., Noda Y., Kamei H., Nagai T., Furukawa H., Miura H., Kayukawa Y., Ohta T., and Nabeshima T. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 12 (2001) 11-15
75. Raedler T.J., Knable M.B., and Weinberger D.R. Schizophrenia as a developmental disorder of the cerebral cortex. Curr. Opin. Neurobiol. 8 (1998) 157-161
76. Rainey Jr. J.M., and Crowder M.K. Prolonged psychosis attributed to phencyclidine: report of three cases. Am. J. Psychiatry 132 (1975) 1076-1078
77. Reynolds G.P., Abdul-Monim Z., Neill J.C., and Zhang Z.J. Calcium binding protein markers of GABA deficits in schizophrenia-post mortem studies and animal models. Neurotox. Res. 6 (2004) 57-62
78. Reynolds L.M., Cochran S.M., Morris B.J., Pratt J.A., and Reynolds G.P. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophr. Res. 73 (2005) 147-152
79. Rice S.R., Niu N., Berman D.B., Heston L.L., and Sobell J.L. Identification of single nucleotide polymorphisms (SNPs) and other sequence changes and estimation of nucleotide diversity in coding and flanking regions of the NMDAR1 receptor gene in schizophrenic patients. Mol. Psychiatry 6 (2001) 274-284
80. Rodefer J.S., Murphy E.R., and Baxter M.G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur. J. Neurosci. 21 (2005) 1070-1076
81. Rosenheck R., Perlick D., Bingham S., Liu-Mares W., Collins J., Warren S., Leslie D., Allan E., Campbell E.C., Caroff S., Corwin J., Davis L., Douyon R., Dunn L., Evans D., Frecska E., Grabowski J., Graeber D., Herz L., Kwon K., Lawson W., Mena F., Sheikh J., Smelson D., and Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290 (2003) 2693-2702
82. Rossler W., Salize H.J., van Os J., and Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur. Neuropsychopharmacol. 15 (2005) 399-409
83. Rushe T.M., Woodruff P.W.R., Murray R.M., and Morris R.G. Episodic memory and learning in patients with chronic schizophrenia. Schizophr. Res. 35 (1999) 85-96
84. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav. Pharmacol. 6 (1995) 55-65
85. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 7 (1996) 3-23
86. Scheetz A.J., and Constantine-Paton M. Modulation of NMDA receptor function: implications for vertebrate neural development. FASEB J. 8 (1994) 745-752
87. Shatz C.J. Impulse activity and the patterning of connections during CNS development. Neuron 5 (1990) 745-756
88. Sircar R. Postnatal phencyclidine-induced deficit in adult water maze performance is associated with N-methyl-d-aspartate receptor upregulation. Int. J. Dev. Neurosci. 21 (2003) 159-167
89. Stefani M.R., and Moghaddam B. Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat. Behav. Brain Res. 134 (2002) 267-274
90. Sturgeon R.D., Fessler R.G., London S.F., and Meltzer H.Y. Behavioral effects of chronic phencyclidine administration in rats. Psychopharmacology 76 (1982) 52-56
91. Sturgeon R.D., Fessler R.G., and Meltzer H.Y. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur. J. Pharmacol. 59 (1979) 169-179
92. Takahashi M., Kakita A., Futamura T., Watanabe Y., Mizuno M., Sakimura K., Castren E., Nabeshima T., Someya T., and Nawa H. Sustained brain-derived neurotrophic factor up-regulation and sensorimotor gating abnormality induced by postnatal exposure to phencyclidine: comparison with adult treatment. J. Neurochem. 99 (2006) 770-780
93. Takahashi M., Billups B., Rossi D., Sarantis M., Hamann M., and Attwell D. The role of glutamate transporters in glutamate homeostasis in the brain. J. Exp. Biol. 200 Pt 2 (1997) 401-409
94. Wang C.Z., and Johnson K.M. Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. J. Neurosci. Res. 81 (2005) 284-292
95. Wang C.Z., and Johnson K.M. The role of caspase-3 activation in phencyclidine-induced neuronal death in postnatal rats. Neuropsychopharmacology 32 (2007) 1178-1194
96. Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J.L., and Johnson K.M. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107 (2001) 535-550
97. Wang C., McInnis J., West J.B., Bao J., Anastasio N., Guidry J.A., Ye Y., Salvemini D., and Johnson K.M. Blockade of phencyclidine-induced cortical apoptosis and deficits in prepulse inhibition by M40403, a superoxide dismutase mimetic. J. Pharmacol. Exp. Ther. 304 (2003) 266-271
98. Weinberger D.R. Schizophrenia and the frontal lobe. Trends Neurosci. 11 (1988) 367-370
99. Wiley J.L., Buhler K.G., Lavecchia K.L., and Johnson K.M. Pharmacological challenge reveals long-term effects of perinatal phencyclidine on delayed spatial alternation in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 867-873
100. Wolkin A., Sanfilipo M., Wolf A.P., Angrist B., Brodie J.D., and Rotrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch. Gen. Psychiatry 49 (1992) 959-965
101. Yamamoto B.K., and Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14 (1994) 4159-4166